Selling the Roadmap
How a $4 billion healthcare AI company sold a future it had already stopped being able to build
The Situation
There’s a term that circulated in banking circles for years to describe a particular kind of technology solution. RFOP. Room Full Of People. The product worked — it just worked because of the humans operating it, not because of the technology being sold. The pitch was automation. The reality was sneakers.
Olive AI was the most expensive RFOP in healthcare technology history.
It didn’t start that way. In 2012, Sean Lane founded a company called CrossChx in Columbus, Ohio — a patient identity management platform built around fingerprint recognition. The original idea was legitimate: link patient medical records to a single verified identity to improve care, reduce costs, and prevent fraud. CrossChx raised tens of millions across several rounds and built a genuine if modest business in healthcare administration.
Then in 2017, with growth stalling and the original revenue model failing to scale, the company rebranded. CrossChx became Olive AI. The fingerprint business became an AI and RPA platform for healthcare automation. The pivot was not driven primarily by a technological breakthrough. It was driven by the recognition that AI commanded a fundamentally different class of investor attention and a fundamentally higher valuation multiple than identity management software. The narrative gap between what the product was and what it was being sold as wasn’t a mistake that emerged from optimism. It was architectural. It was built into the rebrand.
Olive raised roughly $902 million in venture capital, achieved a $4 billion valuation, and deployed its platform across more than 900 hospitals in over 40 US states. At its peak it employed around 1,200 people. It was the kind of company that made the cover of healthcare trade publications and the shortlist of every hospital system’s digital transformation agenda.
On October 31, 2023, Olive announced it was shutting down entirely. Waystar paid roughly $10 million for the clearinghouse and patient access units — what the company itself had described as the heart of its business. Roughly $902 million raised and a $4 billion valuation had resolved, two years later, into a $10 million sale of the core and a wind-down of the rest.
From $4 billion to immaterial in two years. The question worth asking isn’t what went wrong. It’s when the sequence of decisions that made this outcome nearly inevitable actually began.
The answer, it turns out, is 2017. The moment the narrative and the product formally separated.
What Actually Happened
The stated rationale at every stage was growth. More hospitals. More use cases. More capital deployed against a massive market opportunity. Lane was building the operating system for healthcare administration and the window was open. Move fast, capture the market, figure out the margins later.
What was actually happening beneath that rationale was a gap — between what Olive was selling and what Olive was delivering — that widened with every new contract signed and every new dollar raised.
Despite the AI branding, Olive’s platform was primarily built on brittle RPA scripts that failed to scale or integrate seamlessly with healthcare systems. RPA — robotic process automation — is a legitimate technology. It is also a considerably less sophisticated and less defensible product than artificial intelligence. The gap between what RPA actually does and what the phrase “healthcare AI” implies in a sales conversation is significant. Olive lived in that gap for years.
When the scripts failed — and they failed regularly in the complex, non-standardized environment of hospital IT systems — human workers fixed the errors behind the scenes. The automation wasn’t autonomous. It was a room full of people in sneakers, running between screens, manually completing what the pitch deck called AI-driven workflow automation. The product worked. Just not the way it was sold.
That gap was the original distortion. Every decision that followed was made in its shadow.
The Distortion Layer
Four distortions operated here, arriving in sequence and compounding with each new round of capital.
First: Incentives — the structure that rewarded the narrative over the product
The decision to sell AI when you have RPA isn’t primarily a technical decision. It was a commercial one — and by 2018 it had become a structural one. The AI label wasn’t just positioning. It was the business model. Hospital systems evaluating vendors weren’t comparing RPA businesses at $4 billion valuations. They were evaluating AI businesses. The label mattered for procurement decisions, for board presentations, for digital transformation narratives that hospital leadership needed to tell their own stakeholders.
The incentive to maintain the AI framing ran in both directions. Olive needed the label to command the valuation. The hospital systems needed the label to justify the investment internally. Every sales conversation that closed on that basis signed a contract that the product would struggle to fulfill. Every contract created an obligation that required more people — the sneaker brigade — to honor manually. Every new hire added to the cost structure that the revenue model couldn’t support.
The incentive to sell the roadmap rather than the product created a compounding operational problem that grew faster than the company’s ability to solve it. Nobody decided to build a fraudulent company. The incentive structure made selling the gap the path of least resistance at every stage — and organizations, like water, find that path without being directed toward it.
The first distortion is the one you can see from outside. The three that follow are the ones that made it impossible to stop — and they are the reason a $4 billion company sold its core for $10 million. They are below, for subscribers.